Valuation : Waverley Pharma Inc.

Market Cap 810K 585K 504K 474K 433K 55.28M 812K 5.6M 2.17M 28.36M 2.2M 2.15M 91.36M P/E 2024
-0.57x
P/E 2025 -2.16x
Enterprise Value 4.21M 3.04M 2.62M 2.46M 2.25M 287M 4.22M 29.11M 11.3M 147M 11.43M 11.18M 475M EV / Sales 2024
7.09x
EV / Sales 2025 3.32x
Free-Float
25.1%
Yield 2024 *
-
Yield 2025 -
1 day-25.00%
Current month-25.00%
3 months+50.00%
Current year-25.00%
1 week 0.02
Extreme 0.015
0.02
1 month 0.02
Extreme 0.015
0.02
Current year 0.01
Extreme 0.01
0.04
1 year 0.01
Extreme 0.01
0.04
3 years 0.01
Extreme 0.01
0.04
5 years 0.01
Extreme 0.01
0.12
10 years 0.01
Extreme 0.01
0.6
Manager TitleAgeSince
Chief Executive Officer - 2020-01-31
Director of Finance/CFO - 2019-12-31
Director TitleAgeSince
Chairman 79 2016-12-13
Director/Board Member 54 2016-12-13
Director/Board Member - 2023-11-21
Date Insider Type Main position Quantity % Market Cap. Importance
8/16/26 Option

Chairman

-10,000,000 18.5185%
6/24/24 Other

Director

0 0%
8/18/21 Other

Chairman

0 0%
Change 5-day change 1-year change 3-year change Capi.($)
-25.00%0.00%0.00%-57.14% 585K
-1.79%-2.27%+50.90%+89.03% 67.98B
-2.06%-0.18%+41.53%+88.17% 64.94B
-0.31%+6.54%-11.39%+457.82% 27.58B
-3.00%-2.90%+39.40%+9.41% 25.74B
+0.86%+1.65%+0.25%-14.78% 26.06B
-1.46%+0.42%+24.07%-18.70% 20.09B
-2.96%-15.21%+210.71%+370.84% 17.16B
-1.49%-4.88%-0.41%+530.26% 14.92B
-0.20%+8.37%+57.87%+159.50% 14.62B
Average -3.74%+0.23%+41.29%+161.44% 27.91B
Weighted average by Cap. -1.52%+0.18%+42.29%+145.08%

Financials

2024 2025
Net sales 475K 344K 296K 278K 254K 32.44M 477K 3.29M 1.28M 16.64M 1.29M 1.26M 53.62M 1.35M 975K 839K 790K 721K 92.1M 1.35M 9.33M 3.62M 47.25M 3.66M 3.58M 152M
Net income -947K -685K -589K -554K -506K -64.63M -950K -6.55M -2.54M -33.16M -2.57M -2.51M -107M -499K -361K -310K -292K -267K -34.07M -501K -3.45M -1.34M -17.48M -1.35M -1.33M -56.31M
Net Debt 2.83M 2.05M 1.76M 1.66M 1.51M 193M 2.84M 19.57M 7.59M 99.1M 7.68M 7.51M 319M 3.4M 2.46M 2.11M 1.99M 1.82M 232M 3.41M 23.51M 9.12M 119M 9.23M 9.03M 383M
Logo Waverley Pharma Inc.
Waverley Pharma Inc. is a biopharmaceutical company engaged in the research, development and commercialization of human therapeutics focused on oncology. It is advancing its PARP-1 pre-clinical development program, which is in the lead optimization stage, in response to the interest in novel PARP-1 inhibitors that demonstrate selective activity against PARP-1 over PARP-2. The lead compound exhibits single-digit nanomolar activity and significant selectivity for PARP-1 over PARP-2, in pre-clinical invitro testing. It has entered into a license, manufacture, supply, marketing and distribution agreement with Reliance Life Sciences Private Limited (Licensor or RLS) by which the Licensor granted the Company an exclusive territorial license to market and sell capecitabine in the United Kingdom (UK) and Germany as well as a non-exclusive territorial license to market and sell temozolomide in the UK. It also has territorial licenses from RLS to two oncologic drugs, pemetrexed and bortezomib.
Employees
-
Date Price Change Volume
26-09-04 $0.0150 -25.00% 20,000
  1. Stock Market
  2. Stocks
  3. WAVE Stock